Myeloma Paper of the Day, June 23rd, suggested by Robert Orlowski
Robert Orlowski shared on X:
“Myeloma Paper of the Day: ARID1A, a member of SWI/SNF chromatin remodeling complex, is required for IRF4 expression and functionally associates with IRF4 protein on chromatin, and SMARCA2/4 inhibitors remain effective in IMiD-resistant myeloma cells.”
Source: Robert Orlowski/X
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma
Authors: Arnold Bolomsky, Michele Ceribelli, Sebastian Scheich, Kristina Rinaldi, Da Wei Huang, Papiya Chakraborty, Lisette Pham, George W. Wright, Tony Hsiao, Vivian Morris, Jaewoo Choi, James D. Phelan, Ronald J. Holewinski, Thorkell Andresson, Jan Wisniewski, Deanna Riley, Stefania Pittaluga, Elizabeth Hill, Craig J. Thomas, Jagan Muppidi, and Ryan M. Young.
ARID1A: AT-Rich Interactive Domain 1A
SWI/SNF: Switch/Sucrose Non-Fermentable
IRF4: Interferon Regulatory Factor 4
SMARCA2/4: SWI/SNF-related Matrix-associated Actin-dependent Regulator of Chromatin Subfamily A member 2/4
IMiD: Immunomodulatory Drug
Other posts featuring Robert Orlowski on OncoDaily.
Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.
Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.
